Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients

Yusuke Matsunaga, Akinobu Hamada, Isamu Okamoto, Ji Ichiro Sasaki, Eiji Moriyama, Hiroto Kishi, Mitsuhiro Matsumoto, Asumi Hira, Hiroshi Watanabe, Hideyuki Saito

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Amrubicin, a synthetic 9-aminoanthracycline agent, was recently approved in Japan for treatment of small-cell lung cancer and non-small-cell lung cancer. Amrubicin is converted enzymatically to the C-13 hydroxy metabolite amrubicinol, which is active and possesses a cytotoxicity 10 to 100 times that of the parent drug. The purpose of this study was to characterize the pharmacokinetics of amrubicin and its active metabolite amrubicinol. Amrubicin was administered on days 1-3 in 16 patients with advanced lung cancer. The pharmacokinetics analysis of amrubicin and amrubicinol was performed by high-performance liquid chromatography. When 45 mg/m amrubicin was administered in a bolus injection once every 24 hours for 3 consecutive days, the areas under the curves (0 to 72 hours) for amrubicin and amrubicinol were 13,490 and 2585 ng·h/mL, respectively. The apparent total clearance (CLapp) of amrubicin was 15.4 L/h. The area-under-the-curve ratio of amrubicinol to amrubicin was 15.1 ± 4.6% (mean ± SD) at doses ranging from 30 to 45 mg/m. Interindividual variability in the enzymatic conversion of amrubicin to amrubicinol was small. In contrast, a large interindividual variability in the CLapp of amrubicin was observed (CV = 49.8%). The areas under the curves of amrubicin and amrubicinol seemed to be associated with the severity of hematologic toxicities. There is a possibility that monitoring of the plasma concentrations of amrubicin and amrubicinol may provide an efficient tool for establishing the optimal dosage of amrubicin in each patient.

Original languageEnglish
Pages (from-to)76-82
Number of pages7
JournalTherapeutic drug monitoring
Volume28
Issue number1
DOIs
Publication statusPublished - Feb 1 2006
Externally publishedYes

Fingerprint

Lung Neoplasms
Pharmacokinetics
Area Under Curve
amrubicin
amrubicinol
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Japan
Parents
High Pressure Liquid Chromatography
Injections

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients. / Matsunaga, Yusuke; Hamada, Akinobu; Okamoto, Isamu; Sasaki, Ji Ichiro; Moriyama, Eiji; Kishi, Hiroto; Matsumoto, Mitsuhiro; Hira, Asumi; Watanabe, Hiroshi; Saito, Hideyuki.

In: Therapeutic drug monitoring, Vol. 28, No. 1, 01.02.2006, p. 76-82.

Research output: Contribution to journalArticle

Matsunaga, Y, Hamada, A, Okamoto, I, Sasaki, JI, Moriyama, E, Kishi, H, Matsumoto, M, Hira, A, Watanabe, H & Saito, H 2006, 'Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients', Therapeutic drug monitoring, vol. 28, no. 1, pp. 76-82. https://doi.org/10.1097/01.ftd.0000185771.82620.ee
Matsunaga, Yusuke ; Hamada, Akinobu ; Okamoto, Isamu ; Sasaki, Ji Ichiro ; Moriyama, Eiji ; Kishi, Hiroto ; Matsumoto, Mitsuhiro ; Hira, Asumi ; Watanabe, Hiroshi ; Saito, Hideyuki. / Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients. In: Therapeutic drug monitoring. 2006 ; Vol. 28, No. 1. pp. 76-82.
@article{b8d385c242bd47c3b6e5fa0d0ea770a6,
title = "Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients",
abstract = "Amrubicin, a synthetic 9-aminoanthracycline agent, was recently approved in Japan for treatment of small-cell lung cancer and non-small-cell lung cancer. Amrubicin is converted enzymatically to the C-13 hydroxy metabolite amrubicinol, which is active and possesses a cytotoxicity 10 to 100 times that of the parent drug. The purpose of this study was to characterize the pharmacokinetics of amrubicin and its active metabolite amrubicinol. Amrubicin was administered on days 1-3 in 16 patients with advanced lung cancer. The pharmacokinetics analysis of amrubicin and amrubicinol was performed by high-performance liquid chromatography. When 45 mg/m amrubicin was administered in a bolus injection once every 24 hours for 3 consecutive days, the areas under the curves (0 to 72 hours) for amrubicin and amrubicinol were 13,490 and 2585 ng·h/mL, respectively. The apparent total clearance (CLapp) of amrubicin was 15.4 L/h. The area-under-the-curve ratio of amrubicinol to amrubicin was 15.1 ± 4.6{\%} (mean ± SD) at doses ranging from 30 to 45 mg/m. Interindividual variability in the enzymatic conversion of amrubicin to amrubicinol was small. In contrast, a large interindividual variability in the CLapp of amrubicin was observed (CV = 49.8{\%}). The areas under the curves of amrubicin and amrubicinol seemed to be associated with the severity of hematologic toxicities. There is a possibility that monitoring of the plasma concentrations of amrubicin and amrubicinol may provide an efficient tool for establishing the optimal dosage of amrubicin in each patient.",
author = "Yusuke Matsunaga and Akinobu Hamada and Isamu Okamoto and Sasaki, {Ji Ichiro} and Eiji Moriyama and Hiroto Kishi and Mitsuhiro Matsumoto and Asumi Hira and Hiroshi Watanabe and Hideyuki Saito",
year = "2006",
month = "2",
day = "1",
doi = "10.1097/01.ftd.0000185771.82620.ee",
language = "English",
volume = "28",
pages = "76--82",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients

AU - Matsunaga, Yusuke

AU - Hamada, Akinobu

AU - Okamoto, Isamu

AU - Sasaki, Ji Ichiro

AU - Moriyama, Eiji

AU - Kishi, Hiroto

AU - Matsumoto, Mitsuhiro

AU - Hira, Asumi

AU - Watanabe, Hiroshi

AU - Saito, Hideyuki

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Amrubicin, a synthetic 9-aminoanthracycline agent, was recently approved in Japan for treatment of small-cell lung cancer and non-small-cell lung cancer. Amrubicin is converted enzymatically to the C-13 hydroxy metabolite amrubicinol, which is active and possesses a cytotoxicity 10 to 100 times that of the parent drug. The purpose of this study was to characterize the pharmacokinetics of amrubicin and its active metabolite amrubicinol. Amrubicin was administered on days 1-3 in 16 patients with advanced lung cancer. The pharmacokinetics analysis of amrubicin and amrubicinol was performed by high-performance liquid chromatography. When 45 mg/m amrubicin was administered in a bolus injection once every 24 hours for 3 consecutive days, the areas under the curves (0 to 72 hours) for amrubicin and amrubicinol were 13,490 and 2585 ng·h/mL, respectively. The apparent total clearance (CLapp) of amrubicin was 15.4 L/h. The area-under-the-curve ratio of amrubicinol to amrubicin was 15.1 ± 4.6% (mean ± SD) at doses ranging from 30 to 45 mg/m. Interindividual variability in the enzymatic conversion of amrubicin to amrubicinol was small. In contrast, a large interindividual variability in the CLapp of amrubicin was observed (CV = 49.8%). The areas under the curves of amrubicin and amrubicinol seemed to be associated with the severity of hematologic toxicities. There is a possibility that monitoring of the plasma concentrations of amrubicin and amrubicinol may provide an efficient tool for establishing the optimal dosage of amrubicin in each patient.

AB - Amrubicin, a synthetic 9-aminoanthracycline agent, was recently approved in Japan for treatment of small-cell lung cancer and non-small-cell lung cancer. Amrubicin is converted enzymatically to the C-13 hydroxy metabolite amrubicinol, which is active and possesses a cytotoxicity 10 to 100 times that of the parent drug. The purpose of this study was to characterize the pharmacokinetics of amrubicin and its active metabolite amrubicinol. Amrubicin was administered on days 1-3 in 16 patients with advanced lung cancer. The pharmacokinetics analysis of amrubicin and amrubicinol was performed by high-performance liquid chromatography. When 45 mg/m amrubicin was administered in a bolus injection once every 24 hours for 3 consecutive days, the areas under the curves (0 to 72 hours) for amrubicin and amrubicinol were 13,490 and 2585 ng·h/mL, respectively. The apparent total clearance (CLapp) of amrubicin was 15.4 L/h. The area-under-the-curve ratio of amrubicinol to amrubicin was 15.1 ± 4.6% (mean ± SD) at doses ranging from 30 to 45 mg/m. Interindividual variability in the enzymatic conversion of amrubicin to amrubicinol was small. In contrast, a large interindividual variability in the CLapp of amrubicin was observed (CV = 49.8%). The areas under the curves of amrubicin and amrubicinol seemed to be associated with the severity of hematologic toxicities. There is a possibility that monitoring of the plasma concentrations of amrubicin and amrubicinol may provide an efficient tool for establishing the optimal dosage of amrubicin in each patient.

UR - http://www.scopus.com/inward/record.url?scp=33745511197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745511197&partnerID=8YFLogxK

U2 - 10.1097/01.ftd.0000185771.82620.ee

DO - 10.1097/01.ftd.0000185771.82620.ee

M3 - Article

C2 - 16418698

AN - SCOPUS:33745511197

VL - 28

SP - 76

EP - 82

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 1

ER -